cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
cometriq
ipsen pharma - cabozantinib - thyroid neoplasms - antineoplastiske midler - behandling af voksne patienter med progressiv, inoperabel lokalt fremskreden eller metastatisk medullær thyroid carcinoma.
ciclosporin "actavis" 100 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 100 mg
ciclosporin "actavis" 25 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 25 mg
ciclosporin "actavis" 50 mg kapsler, bløde
actavis group ptc ehf. - ciclosporin - kapsler, bløde - 50 mg
ciqorin 100 mg kapsler, bløde
teva b.v. - ciclosporin - kapsler, bløde - 100 mg
ciqorin 25 mg kapsler, bløde
teva b.v. - ciclosporin - kapsler, bløde - 25 mg
ciqorin 50 mg kapsler, bløde
teva b.v. - ciclosporin - kapsler, bløde - 50 mg
sandimmun neoral 100 mg kapsler, bløde
novartis healthcare a/s - ciclosporin - kapsler, bløde - 100 mg
sandimmun neoral 100 mg kapsler, bløde
orifarm a/s - ciclosporin - kapsler, bløde - 100 mg